Johnson & Johnson (JNJ) is a leading drug manufacturers—general business based in the US. It opened the day at $147.48 after a previous close of $144.21. During the day the price has varied from a low of $144.38 to a high of $147.55. The latest price was $144.44 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 132,200 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Johnson & Johnson's share price has had significant negative movement.
Its last market close was $144.44, which is 3.66% down on its pre-crash value of $149.93 and 32.32% up on the lowest point reached during the March crash when the shares fell as low as $109.16.
If you had bought $1,000 worth of Johnson & Johnson shares at the start of February 2020, those shares would have been worth $740.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $961.97.
|52-week range||$109.16 - $157|
|50-day moving average||$149.6276|
|200-day moving average||$144.5329|
|Wall St. target price||$165.06|
|Dividend yield||$4.04 (2.75%)|
|Earnings per share (TTM)||$5.684|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-09-14)||-2.64%|
|1 month (2020-08-24)||-5.07%|
|3 months (2020-06-24)||3.30%|
|6 months (2020-03-24)||21.19%|
|1 year (2019-09-20)||9.72%|
|2 years (2018-09-21)||1.09%|
|3 years (2017-09-21)||9.63%|
|5 years (2015-09-21)||55.10%|
Valuing Johnson & Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson & Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Johnson & Johnson shares trade at around 26x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Johnson & Johnson's P/E ratio is best considered in relation to those of others within the drug manufacturers—general industry or those of similar companies.
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.1851. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Johnson & Johnson's PEG ratio in relation to those of similar companies.
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $27.2 billion (£21.4 billion).
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
To put Johnson & Johnson's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$80.5 billion|
|Operating margin TTM||25.09%|
|Gross profit TTM||$54.6 billion|
|Return on assets TTM||8.05%|
|Return on equity TTM||24.54%|
|Market capitalisation||$404 billion|
TTM: trailing 12 months
There are currently 10.6 million Johnson & Johnson shares held short by investors – that's known as Johnson & Johnson's "short interest". This figure is 14.8% down from 12.4 million last month.
There are a few different ways that this level of interest in shorting Johnson & Johnson shares can be evaluated.
Johnson & Johnson's "short interest ratio" (SIR) is the quantity of Johnson & Johnson shares currently shorted divided by the average quantity of Johnson & Johnson shares traded daily (recently around 5.4 million). Johnson & Johnson's SIR currently stands at 1.96. In other words for every 100,000 Johnson & Johnson shares traded daily on the market, roughly 1960 shares are currently held short.
To gain some more context, you can compare Johnson & Johnson's short interest ratio against those of similar companies.
However Johnson & Johnson's short interest can also be evaluated against the total number of tradable Johnson & Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson & Johnson's short interest could be expressed as 0.004% of the tradable shares (for every 100,000 tradable Johnson & Johnson shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson & Johnson.
Find out more about how you can short Johnson & Johnson stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson & Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.78
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson & Johnson's overall score of 35.78 (as at 08/01/2020) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson & Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Johnson & Johnson's total ESG risk score against those of similar companies.
Environmental score: 3.79/100
Johnson & Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 25.14/100
Johnson & Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson & Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 15.85/100
Johnson & Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson & Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Johnson & Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson & Johnson has a damaged public profile.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||35.78|
|Total ESG percentile||72.34|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||4|
Dividend payout ratio: 67.84% of net profits
Recently Johnson & Johnson has paid out, on average, around 67.84% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.75% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson & Johnson shareholders could enjoy a 2.75% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $4.04 per share.
Johnson & Johnson's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Johnson & Johnson's most recent dividend payout was on 8 September 2020. The latest dividend was paid out to all shareholders who bought their shares by 24 August 2020 (the "ex-dividend date").
Johnson & Johnson's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Johnson & Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson & Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson & Johnson shares which in turn could have impacted Johnson & Johnson's share price.
Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $109.16 up to $157. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.6817. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).
To put Johnson & Johnson's beta into context you can compare it against those of similar companies.
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.